Thymomas and thymic carcinomas are rare thoracic malignancies with limited clinical trial evidence. The study reviewed here sought to characterize real-world treatment practices for patients with Stage III and Stage IV thymoma or thymic carcinoma diagnosed between 2018 and 2022 across Japan. The primary goals were to document the frequency of perioperative treatments, radiotherapy use after surgery, uptake of newer systemic therapies, and the specific chemotherapy regimens applied in routine care.
Cases included in the analysis were identified through a nationwide dataset that linked the Hospital-based Cancer Registry with the Diagnosis Procedure Combination (DPC) survey. This linked administrative and registry resource enabled capture of diagnosis stage and treatment patterns for the study period (2018–2022). The investigators summarized use of perioperative chemotherapy (preoperative and postoperative), radiotherapy after complete resection, and first-line systemic chemotherapy regimens among the cohorts. The abstract reports aggregate frequencies and proportional trends over time.
The study identified the following groups of patients recorded in the registry and DPC linkage:
These counts form the basis for subsequent comparisons of treatment modalities and regimen selection between thymoma and thymic carcinoma.
After complete surgical resection, the use of postoperative radiotherapy differed notably between histologies. For Stage III disease, postoperative radiotherapy was more commonly administered in patients with thymic carcinoma than in those with thymoma: 34.1% for Stage III thymic carcinoma versus 10.7% for Stage III thymoma. The analysis also reports a temporal decrease in postoperative radiotherapy for Stage III thymoma over the study interval (see Trends section).
Patterns of perioperative chemotherapy for Stage IV disease varied by histology. Perioperative treatment (preoperative or postoperative chemotherapy) was more frequently used in Stage IV thymoma than in Stage IV thymic carcinoma. Specifically, preoperative chemotherapy was recorded in 15.5% of Stage IV thymoma cases compared with 3.7% of Stage IV thymic carcinoma cases. Postoperative chemotherapy was recorded in 8.4% of Stage IV thymoma cases versus 4.4% for Stage IV thymic carcinoma.
These differences indicate a greater tendency to incorporate systemic therapy around surgery in advanced thymoma relative to thymic carcinoma within Japanese practice during the study period.
Regimen choice for Stage IV disease showed clear histology-specific predominance. In Stage IV thymoma, the most commonly used systemic chemotherapy regimen was adriamycin‑cisplatin‑vincristine‑cyclophosphamide, accounting for 41.8% of regimens reported. In contrast, Stage IV thymic carcinoma patients were treated predominantly with carboplatin‑paclitaxel, used in 99.5% of Stage IV thymic carcinoma cases.
These findings reflect divergent standard-of-care chemotherapy preferences between thymoma and thymic carcinoma in Japan during 2018–2022.
The study documented changes in treatment proportions over the evaluated years. Two specific temporal trends reported in the abstract were:
No additional temporal details, subgroup analyses, or explanations for these shifts were provided in the abstract. The source did not report granular outcome data, toxicity, or survival associated with these practice changes in the abstract.
The nationwide analysis concludes that evidence-based treatment approaches for thymoma and thymic carcinoma have been widely adopted in Japan between 2018 and 2022. The reported histology-specific patterns—greater postoperative radiotherapy in Stage III thymic carcinoma, more perioperative chemotherapy in Stage IV thymoma, predominant use of adriamycin‑based combination regimens for thymoma, and near-universal use of carboplatin‑paclitaxel for thymic carcinoma—illustrate how registry-linked real-world data capture standard practice. The abstract emphasizes uptake of guideline-consistent therapies but does not present outcomes or causal explanations for the observed temporal trends.
Note: Details beyond what appears in the article abstract, such as survival outcomes, adverse events, institutional variation, or reasons for regimen selection, were not reported in the source abstract.